The endocannabinoid system’s discovery has created debate on its conclusions on human health. Because of its capability to target various therapeutic agents that are in different states of disease has piqued interest for researchers.
Some researchers suggest the endocannabinoid system plays a vital role in cellular homeostasis. This could mean that the health of this system could affect the health of the whole body.
Table of Contents
This article reviews the basics of the endocannabinoid system and its role in cardiovascular and neurological health and specifically, endocannabinoid system deficiency and the adverse effects on the other body’s systems.
The endocannabinoid system is comprised of two receptors and a series of internally produced compounds. The two main receptors in the endocannabinoid system are the CB1 and CB2 receptors.
N-arachidonoylethanolamine (AEA).
AEA increases in times of oxidative stress, inflammation or cell death. Researchers believe that it may be produced as a response to injury when counteracting inflammatory activity. This activity could be the evidence of the systems role in cellular homeostasis.
CB1 and CB2 receptors are found throughout the body. CB1 receptors are primarily found in the nervous system, while CB2 receptors are primarily found in intestinal epithelium cells and immune system cells.
CB1 receptors predominantly interact with THC and other psychoactive compounds from the cannabis plant. This is a logical find because the CB1 receptors are found primarily in the nervous system. This interaction of CB1 receptors and THC could cause certain changes in brain chemistry, which leads to the euphoric feeling produced from cannabis use.
CB2 receptors interact with cannabidiol (CBD) which is a secondary major compound in cannabis. This does not mean that CBD does not interact with CB1 receptors ever, but because these interactions are quite uncommon they are considered unimportant. Because CBD does not have compelling interaction with CB1 receptors, the psychoactive effects from THC are not present.
Both cannabinoid compounds have therapeutic potential. Studies have found these compounds help control chronic inflammation in conditions like IBS (irritable bowel syndrome).
CBD contains the same therapeutic properties as THC, without the psychoactive effects. CBD is under extensive research, as a compound that can help with various diseases and their progression. This has led researchers to create synthetic compounds that mimic CBD and its interaction with CB2 receptors.
Depending on the receptors involved cardiovascular health, and the endocannabinoid system’s activation could lead to beneficial or conflicting effects.
CB1 receptors have been linked to an increase of cardiovascular disease or cardiovascular incidents. Incidents include heart attack, atherosclerosis (plaque inside the blood vessels ), stroke, kidney dysfunction and liver problems. Animal models and epidemiological studies have shown these findings.
The difference between CBD and THC:
THC use, as a therapeutic agent could increase risk of cardiovascular incidents from interaction with CB1 receptors. But CBD also interacts with CB2 receptors and is possible that administration of CBD could lead to cardioprotective effects.
Various research reports show neural-progenitor cells produce endocannabinoids in time of injury and stress. This stimulates cell division in the brain, especially in areas like the hippocampus and sub-ventricles. This division is believed to be produced through interaction of endocannabinoids and CB1 receptors.
AEA, for example, induces astroglial proliferation in mice. Astroglia are star-shaped neurons thought to be extremely important for brain structure and protection. These are found in various areas like the blood brain barrier. Pharmacological stimulation of CB1 using synthetic cannabinoids has lead to neurogenesis or new growth of nervous tissue.
Synthetic cannabinoids could be beneficial not just for brain injuries, but could also be utilized as an antidepressant. The synthetic cannabinoid HU210 has been used for this purpose from its ability to modulate the endocannabinoid system and increase neural growth.
Recent studies show that CB1-deficient mice tend to suffer from early age related cognitive impairment or a noticeable and measurable decline in cognitive abilities, which include memory and thinking skills. This could be because CB1 deficient mice cannot regenerate cells in the nervous system, making them succumb faster to age related cellular death. But this is a perfect example of endocannabinoid system deficiencies, which could lead to detrimental effects in humans.
Professional Scope of Practice *
The information herein on "Endocannabinoid System And The Human Body" is not intended to replace a one-on-one relationship with a qualified health care professional or licensed physician and is not medical advice. We encourage you to make healthcare decisions based on your research and partnership with a qualified healthcare professional.
Blog Information & Scope Discussions
Our information scope is limited to Chiropractic, musculoskeletal, physical medicines, wellness, contributing etiological viscerosomatic disturbances within clinical presentations, associated somatovisceral reflex clinical dynamics, subluxation complexes, sensitive health issues, and/or functional medicine articles, topics, and discussions.
We provide and present clinical collaboration with specialists from various disciplines. Each specialist is governed by their professional scope of practice and their jurisdiction of licensure. We use functional health & wellness protocols to treat and support care for the injuries or disorders of the musculoskeletal system.
Our videos, posts, topics, subjects, and insights cover clinical matters, issues, and topics that relate to and directly or indirectly support our clinical scope of practice.*
Our office has reasonably attempted to provide supportive citations and has identified the relevant research study or studies supporting our posts. We provide copies of supporting research studies available to regulatory boards and the public upon request.
We understand that we cover matters that require an additional explanation of how it may assist in a particular care plan or treatment protocol; therefore, to further discuss the subject matter above, please feel free to ask Dr. Alex Jimenez, DC, or contact us at 915-850-0900.
We are here to help you and your family.
Blessings
Dr. Alex Jimenez DC, MSACP, RN*, CCST, IFMCP*, CIFM*, ATN*
email: coach@elpasofunctionalmedicine.com
Licensed as a Doctor of Chiropractic (DC) in Texas & New Mexico*
Texas DC License # TX5807, New Mexico DC License # NM-DC2182
Licensed as a Registered Nurse (RN*) in Florida
Florida License RN License # RN9617241 (Control No. 3558029)
License Compact Status: Multi-State License: Authorized to Practice in 40 States*
Presently Matriculated: ICHS: MSN* FNP (Family Nurse Practitioner Program)
Dr. Alex Jimenez DC, MSACP, RN* CIFM*, IFMCP*, ATN*, CCST
My Digital Business Card
Yips are involuntary wrist muscle spasms that affect athletes. They are often associated with golf,… Read More
For individuals dealing with newly formed or chronic lower back pain, can making daily walks… Read More
Can bioidentical hormone replacement therapy can help many individuals dealing with pain and fatigue while… Read More
For many individuals, getting on the floor to do crunches or other exercises can be… Read More
The iliacus muscle is a triangle-shaped muscle in the pelvic bone that flexes and rotates… Read More
Incorrect manual handling and lifting is a leading cause of workplace injuries. Can health and… Read More